Date: 2014-06-24
Type of information: Production agreement
Compound: Paclical, Paccal Vet®-CA1, future Oasmia products
Company: Oasmia Pharmaceutical (Sweden) Baxter (USA - IL)
Therapeutic area: Cancer - Oncology
Type agreement:
Action mechanism:
Disease:
Details: * On June 24, 2014, Oasmia Pharmaceutical announced that it has extended its production collaboration with Baxter\'s BioPharma Solutions around Oasmia\'s products. Oasmia and Baxter’s BioPharma Solutions, which is the contract manufacturing arm of Baxter International , has signed a Master Manufacturing Agreement to cover future Oasmia products today in clinical or development phase. This agreement is a compliment to the already existing Contract Manufacturing Agreement for Oasmia’s two oncology products Paclical and Paccal Vet®-CA1. Oasmia and Baxter have recently successfully transferred and validated large scale production of Paclical and Paccal Vet-CA1at the Baxter Halle facility and is expected to be approved by the authorities well in time for expected increased market demands of Oasmia’s products. The extension of the agreement means that Oasmia can source products both from its own Uppsala plant and Baxter’s plant.
Financial terms:
Latest news:
